2021
Rates of COVID-19 Among Residents and Staff Members in Nursing Homes — United States, May 25–November 22, 2020
Bagchi S, Mak J, Li Q, Sheriff E, Mungai E, Anttila A, Soe M, Edwards J, Benin A, Pollock D, Shulman E, Ling S, Moody-Williams J, Fleisher L, Srinivasan A, Bell J. Rates of COVID-19 Among Residents and Staff Members in Nursing Homes — United States, May 25–November 22, 2020. MMWR Morbidity And Mortality Weekly Report 2021, 70: 52-55. PMID: 33444301, PMCID: PMC7808710, DOI: 10.15585/mmwr.mm7002e2.Peer-Reviewed Original ResearchConceptsNational Healthcare Safety NetworkNursing home residentsCOVID-19 casesHome residentsHigh riskNursing homesCDC's National Healthcare Safety NetworkCOVID-19Certain underlying medical conditionsSARS-CoV-2 transmissionUnderlying medical conditionsNursing home staff membersCoronavirus disease 2019 (COVID-19) pandemicHuman Services (HHS) regionsSARS-CoV-2Disease 2019 pandemicStaff membersHome staff membersCOVID-19 ratesCOVID-19 incidenceHigh-risk exposureSevere outcomesCongregate settingsMedical conditionsGeneral population
2003
Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults
Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG. Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults. The Journal Of Infectious Diseases 2003, 188: 81-89. PMID: 12825175, DOI: 10.1086/375782.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseOverall vaccine effectivenessNavajo adultsPneumococcal diseaseCase patientsControl patientsPolysaccharide vaccineVaccine effectivenessGeneral United States populationSerious pneumococcal diseasePneumococcal polysaccharide vaccineCohort methodologyUnited States populationCase-control setsActive surveillanceObservational studyMedical conditionsPatientsMedical careDiseaseAdultsDiabetesRegression analysisVaccineAlcoholism